Cargando…

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update

At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of developing metastasis and subsequent disease-rel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biswas, S, Wrigley, J, East, C, Hern, A, Marshall, A, Dunn, J, Lorigan, P, Middleton, M, Corrie, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2008
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234061/ https://www.ncbi.nlm.nih.gov/pubmed/22275984 http://dx.doi.org/10.3332/ecancer.2008.108

Ejemplares similares

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
por: Zhang, Shujing, et al.
Publicado: (2023)

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
por: Lipplaa, Astrid, et al.
Publicado: (2018)

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
por: Corrie, P G, et al.
Publicado: (2018)

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
por: Corrie, P G, et al.
Publicado: (2019)

Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer
por: Li, Hongbo, et al.
Publicado: (2020)

Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
por: Kruijff, S., et al.
Publicado: (2011)

A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden
por: Isaksson, Karolin, et al.
Publicado: (2019)

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
por: Lee, R J, et al.
Publicado: (2018)

The Divergent CD8(+) T Cell Adjuvant Properties of LT-IIb and LT-IIc, Two Type II Heat-Labile Enterotoxins, Are Conferred by Their Ganglioside-Binding B Subunits
por: Hu, John C., et al.
Publicado: (2015)

Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas
por: Chu, Vicki H., et al.
Publicado: (2013)

Studies of the expression of the cytochrome P450IA, P450IIB, and P450IIC gene family in extrahepatic and hepatic tissues.
por: Friedberg, T, et al.
Publicado: (1990)

What is the optimal surgical treatment for Neer type IIB (IIC) distal clavicle fractures? A systematic review and meta-analysis
por: Panagopoulos, Andreas, et al.
Publicado: (2022)

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study
por: Mordoh, José, et al.
Publicado: (2017)

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)
por: Lotem, M, et al.
Publicado: (2002)

Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
por: Christofyllakis, Konstantinos, et al.
Publicado: (2021)

Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient
por: Brokāne, Linda, et al.
Publicado: (2019)

Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients
por: Mactier, Swetlana, et al.
Publicado: (2014)

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma
por: Hynes, Matthew C., et al.
Publicado: (2022)

DDA1 promotes stage IIB–IIC colon cancer progression by activating NFκB/CSN2/GSK-3β signaling
por: Zhao, Senlin, et al.
Publicado: (2016)

Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins
por: Lee, Jooyoung, et al.
Publicado: (2018)

Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients
por: Kaufman, Kimberley L., et al.
Publicado: (2014)

Periodontal Microsurgical-Assisted Pouch and Tunnel Approach in Combination with Subepithelial Connective Tissue Graft for the Management of Class IIB and IIC Multiple Adjacent Gingival Recessions in Mandibular Anterior Segment
por: Salaria, Sanjeev Kumar, et al.
Publicado: (2018)

Unilateral transnasal endoscopic approach to frontal sinuses: Draf IIc
por: Al Komser, Mohammed K., et al.
Publicado: (2013)

Inhibitory mechanism of CRISPR-Cas9 by AcrIIC4
por: Li, Xuzichao, et al.
Publicado: (2023)

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage
por: Teterycz, Pawel, et al.
Publicado: (2019)

Dermoscopic characteristics of melanoma according to the criteria „ulceration“ and „mitotic rate“ of the AJCC 2009 staging system for melanoma
por: Deinlein, Teresa, et al.
Publicado: (2017)

Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology
por: Bannoud, Nadia, et al.
Publicado: (2023)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

Systemic adjuvant therapy for high-risk cutaneous melanoma
por: Kobeissi, Iyad, et al.
Publicado: (2022)

S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients
por: Deckers, Eric A., et al.
Publicado: (2019)

Intradermal Administration of the Type II Heat-Labile Enterotoxins LT-IIb and LT-IIc of Enterotoxigenic Escherichia coli Enhances Humoral and CD8(+) T Cell Immunity to a Co-Administered Antigen
por: Hu, John C., et al.
Publicado: (2014)

ASO Author Reflections: The MelFo-Study, UK: Effects of a Reduced Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma IB–IIC Patients After 3 Years
por: Moncrieff, Marc, et al.
Publicado: (2020)

Transitions between the steps of forward and reverse splicing of group IIC introns
por: Smathers, Claire M., et al.
Publicado: (2020)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

AJCC cancer staging manual
Publicado: (1998)

The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB–IIC Patients—Results After 3 Years
por: Deckers, Eric A., et al.
Publicado: (2019)

Adjuvant interferon in the treatment of melanoma – reply
por: Middleton, M R
Publicado: (2000)

Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib
por: Tudor, Diana Valentina, et al.
Publicado: (2021)

Comparative Analysis of the “Scholastic” Recommendations of the AJCC From 2011 for the Surgical Treatment of Cutaneous Melanoma with the Newly Suggested Guidelines for OSMS From the Bulgarian Society For Dermatologic Surgery!
por: Tchernev, Georgi, et al.
Publicado: (2018)

Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach
por: You, Min Su, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0q7ecanmqsnhfma6h4j5h7pm06